# A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Received Three or More Lines of Therapy

> **NCT05998928** · PHASE2 · RECRUITING · sponsor: **Union Hospital, Tongji Medical College, Huazhong University of Science and Technology** · enrollment: 10 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Fludarabine + Cyclophosphamide + BCMA-GPRC5D CAR-T Cells

## Key facts

- **NCT ID:** NCT05998928
- **Lead sponsor:** Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-27
- **Primary completion:** 2025-07-27
- **Final completion:** 2026-07-27
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2023-11-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05998928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05998928, "A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Received Three or More Lines of Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05998928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*